

#### **EYSUVIS**

(loteprednol etabonate ophthalmic suspension)

#### **Pre - PA Allowance**

None

# **Prior-Approval Requirements**

Age 18 years of age or older

**Diagnosis** 

Patient must have the following:

- 1. Dry eye disease
  - a. Patient has had an ocular examination under magnification such as slit lamp
  - NO dual therapy with another legend ophthalmic for the treatment of dry eyes (see Appendix 1)

### **Prior - Approval Limits**

**Quantity** 2 bottles

**Duration** 1 month

## Prior – Approval Renewal Requirements

Age 18 years of age or older

**Diagnosis** 

Patient must have **ALL** of the following:

### If further treatment is needed after 2 weeks

- 1. Dry eye disease
  - a. Patient has had an improvement in symptoms to justify renewal in treatment
  - b. Patient has had an ocular examination under magnification such as slit lamp
  - c. Patient has had an evaluation for intraocular pressure
  - NO dual therapy with another legend ophthalmic for the treatment of dry eyes (see Appendix 1)



#### **EYSUVIS**

(loteprednol etabonate ophthalmic suspension)

# Prior - Approval Renewal Limits

Same as above

#### **Appendix 1 - List of Legend Ophthalmic Medications for Dry Eye**

Generic Name	Brand Name
cyclosporine	Cequa
cyclosporine	Restasis
cyclosporine	Vevye
lifitegrast	Xiidra
loteprednol	Eysuvis
perfluorohexyloctane	Miebo
varenicline	Tyrvaya

<sup>\*</sup>Verkazia is not approved for dry eye